Select therapeutic use:
Indications for RESCRIPTOR:
Swallow whole or may disperse 100mg tabs in 3oz water and drink. ≥16yrs: 400mg 3 times daily.
<16yrs: not established.
CYP3A substrates that may cause serious events if blood levels are elevated (eg, cisapride, pimozide, alprazolam, midazolam, triazolam, ergots).
Discontinue if serious rash (or rash with other symptoms) occurs. Hepatic dysfunction. Achlorhydria (take with an acidic beverage). Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Concomitant lovastatin or simvastatin, NNRTIs: not recommended. May increase levels of antiarrhythmics (eg, bepridil, quinidine), calcium channel blockers (eg, nifedipine), clarithromycin, rifabutin, indinavir, saquinavir, maraviroc, amphetamines, trazodone, warfarin, sildenafil, atorvastatin, cerivastatin, fluvastatin, immunosuppressants, methadone, fluticasone (long-term use), ethinyl estradiol; serious or life-threatening adverse reactions may occur with some of these drugs (avoid or adjust dose). Delavirdine levels may be decreased by phenytoin, phenobarbital, carbamazepine, rifabutin, rifampin, chronic H2 antagonists or PPIs, dexamethasone, St. John's wort: not recommended; didanosine and vice versa (separate dosing by at least 1 hour). Delavirdine levels increased by fluoxetine, ketoconazole. Absorption reduced by antacids (separate dosing by at least 1 hour). Reduce indinavir dose (consider indinavir 600mg three times daily).
Non-nucleoside reverse transcriptase inhibitor.
Rash, GI upset, increased ALT/AST; immune reconstitution syndrome, autoimmune disorders (eg, Graves' disease, polymyositis, Guillain-Barre syndrome), fat redistribution.
Hepatic (CYP3A); 98% protein bound.
Tabs 100mg—360; 200mg—180